Content about Epoetin alfa

October 31, 2012

Generic drug maker Sandoz has started a late-stage clinical trial in the United States for a biosimilar treatment for anemia, the company said.

HOLZKIRCHEN, Germany — Generic drug maker Sandoz has started a late-stage clinical trial in the United States for a biosimilar treatment for anemia, the company said.

Sandoz, the generics arm of Swiss drug maker Novartis, said it had started enrolling patients for a phase-3 study of epoetin alfa, a biosimilar version of Epogen and Procrit, made by Amgen and Johnson & Johnson and used to treat anemia associated with chronic kidney disease.

September 23, 2010

Several lots of two drugs used to treat anemia are being recalled due to possible...

THOUSAND OAKS, Calif. Several lots of two drugs used to treat anemia are being recalled due to possible contamination.

 

Amgen said Friday that it was voluntarily recalling certain lots of Epogen and Procrit (epoetin alfa) from distributors, wholesalers, healthcare providers and pharmacies as a precaution due to the possible presence of extremely thin and barely visible glass flakes known as lamellae that result from an interaction between the drugs and the glass vials used to store them.

 

 

August 4, 2010

Biotech company Amgen had $3.8 billion in sales and $1.33 billion in profits during second...

January 6, 2010

The Food and Drug Administration plans to review three drugs designed to treat anemia, according...